trending Market Intelligence /marketintelligence/en/news-insights/trending/9HApN8u64QTXLkSt5AX0HA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA accepts TherapeuticsMD's resubmitted application for pain drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA accepts TherapeuticsMD's resubmitted application for pain drug

The U.S. Food and Drug Administration accepted the new drug application resubmission for TherapeuticsMD Inc.'s TX-004HR.

The drug is meant to treat moderate-to-severe vaginal pain during sexual intercourse, or dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause.

The resubmission includes the 4 mcg and 10 mcg doses of TX-004HR.

According to the company, the FDA acknowledged the resubmission as a complete, class 2 response to the complete response letter received on May 5 for the drug.

The FDA's review is expected to be completed May 29, 2018.

In addition, the agency has informed the company that the additional endometrial safety information submitted to the new drug application for TX-004HR was outside of an official review cycle, thus procedurally designating a class 2 response.

TherapeuticsMD plans to launch TX-004HR in the third quarter of 2018, if approval occurs on or before the expected completion date of the FDA review.

The resubmission is supported by a TX-004HR clinical program, including positive results of the phase 3 trial, which showed statistically significant and clinically meaningful improvements in dyspareunia.